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Understanding the metabolic rewiring of pancreatic ductal 
adenocarcinoma is an emerging strategy to identify cancer-associated 
liabilities and improve treatment. A new study now elucidates the 
function of BCAT2 in the early stages of tumour development, providing 
insights that could stimulate novel therapeutic strategies. 
 
The oncogenic mutations that drive cancer development induce the 
transformed cells to lock into a ‘biosynthetic mode’. Metabolic adaptation is 
crucial for the tumour to meet its energy requirements and to produce the 
biomass necessary to sustain proliferation and survival1. In this rewired 
metabolic network, a central role is played by amino acids, which provide both 
carbon and nitrogen to ensure the production of macromolecules needed to 
enable tumour growth. In vivo studies on non-essential amino acid (NEAA) 
metabolism have shown that both oncogenic and tumour suppressor 
mutations can influence sensitivity to specific dietary NEAA starvation2. On 
the other hand, the metabolism of essential amino acids also plays a crucial 
role in cancer. In particular, the relevance of BCAA metabolism has become 
evident in recent years3, 4. Specifically, either branched chain amino acids 
transaminases 1 or 2 (BCAT1, BCAT2) have been shown to be up-regulated 
and important for proliferation in neoplastic diseases such as glioma, acute 
myeloid leukaemia, non-small cell lung cancer and pancreatic ductal 
adenocarcinoma (PDAC)3, 5-7. The latter is one of the major cancer-related 
causes of death worldwide due to late diagnosis and chemotherapeutic 
resistance8. Despite the efforts to identify new drug targets the viable 
therapeutic options for PDAC remain limited. Previous studies have shown 
increased expression of BCAT2 in the late stage of PDAC3, 7, however the 
potential benefit to the tumour of this upregulation remains unclear. In this 
issue of Nature Cell Biology, Li et al.4 dissect for the first time the molecular 
mechanism by which the BCAA-BCAT2 axis is boosted in the early stages of 
Kras-driven PDAC, and how therapeutic BCAT2 inhibition or dietary BCAA 
restriction slow the onset of the disease. 
 
In order to shed more light on PDAC metabolism, Li et al.4 analysed 
amino acid concentrations in tumour and healthy tissue in a genetically 
engineered mouse model to evaluate the full progression of the disease, from 
pancreatic intraepithelial neoplastic (PanIN) lesions to invasive carcinoma 
(LSL-KrasG12D/+; Pdx1-Cre (KC)). While most of the non-essential amino 
acid levels were unchanged, the concentration of BCAAs was elevated in the 
tumour tissue. Leucine, valine and isoleucine are essential amino acids and 
can supply carbons and nitrogen to build other macromolecules in the cell9. 
The carbons provided by BCAA oxidation can be processed to acetyl-CoA, 
enter the tricarboxylic acid (TCA) cycle and be used in lipids synthesis9. 
Additionally, nitrogen derived from BCAAs can be utilised for nucleotide 
production9. Li et al. confirmed previous studies that observed the 
upregulation of BCAT2 in the advanced stage of PDAC3, and demonstrated 
that levels of BCAT2, but not BCAT1 were significantly higher in the PDAC 
precursor PanIN lesions. To better validate the role of BCAT2 in the early 
stages of disease development, the authors took advantage of a KC mouse 
model in which Bcat2 could be knocked out in an inducible fashion (KC/Bcat2-
/-). The in vivo Bcat2 deletion not only attenuated the formation of PanIN 
lesions, but also prevented their progression into a more advanced stage and 
mitigated the desmoplasia linked to the disease. 
 
To further corroborate their findings and the relevance of BCAA 
catabolism in PDAC progression, Li et al.4 demonstrated that in vitro 
downregulation of BCAT2 decreased mitochondrial respiration and 
intracellular levels of Leucine-derived non-essential amino  acids like 
Glutamate, Alanine, Serine and Aspartate, as well as nucleotides. In line with 
these results, the authors found a decrease in actively proliferating cells upon 
in vivo Bcat2 knockout. Also, Li et al.4 showed that survival in KC mouse 
models was significantly prolonged in orthotopic transplantation assay with 
either Bcat2 pharmacological inhibition or low-BCAA diet. While these data 
reveal information about the function of BCAT2, further research using 
labelled BCAA could trace their metabolic fate in PDAC development. 
 
Next, the authors asked if the manipulation of Bcat2 expression 
affected the concentration of BCAA-derived acetyl-CoA. Since a recent study 
showed that increased cytosolic acetyl-CoA levels were responsible for 
elevated histone acetylation resulting in acinar-to-ductal metaplasia and 
therefore in PDAC development10, Li et al.4 analysed acetyl-CoA pool and 
histone-lysine acetylation in both acinar and ductal cells. The authors showed 
that upon Bcat2 knockout, acetyl-CoA metabolism and histone acetylation 
was indeed dramatically affected in acinar cells, but not in ductal cells. This 
reinforces their observations in which Bcat2 plays a central role during ductal-
derived PanIN lesions by sustaining BCAA catabolism and thus promoting 
mitochondrial function and providing a nitrogen source. 
 
To gain further insight into the molecular mechanism by which BCAA 
catabolism is up-regulated during PDAC development, Li et al. interrogated 
the effect of KRAS mutation on the expression of BCAT2. The authors 
analysed protein expression in clinical PDAC human specimens and observed 
a positive correlation between the increased levels of BCAT2 and KRAS 
mutation. Then, by manipulating in vitro the expression of KRAS, the authors 
demonstrated that BCAT2 regulation occurs at the protein rather than the 
transcript level. In particular, using a tandem affinity purification and mass 
spectrometry  approach, Li et al. demonstrated that ubiquitination of BCAT2 
was operated by the E3 ligase tripartite motif-containing protein 21 
(TRIM21), and that this process negatively correlates with KRAS 
expression. Next, the authors asked weather binding of TRIM21 was the 
result of a phosphorylation event on BCAT2. Li et al.4 elegantly showed that 
spleen tyrosine kinase (SYK) directs the ubiquitination of BCAT2 by 
phosphorylation of tyrosine 228. Moreover, the authors also showed that the 
expression of SYK has a negative correlation, similar to TRIM21, with KRAS, 
thus explaining how the oncogene up-regulates BCAT2 at the post-
translational level. 
 
Finally, Li et al. focussed on the possible clinical relevance of their 
study by analysing their PDAC mouse model either during a low-BCAA diet or 
treated with long-term inhibition of Bcat2. KC mice fed a low BCAA diet 
displayed a reduction in the overall burden of the PanIN lesions. Notably, the 
low-BCAA diet impaired PDAC progression seemingly without affecting the 
global physiology of the other organs during the treatment. The only tissue 
displaying noticeable changes was the skeletal muscle, which showed fibres 
thinning. Li et al. showed that a regimen of 1/5 of BCAA in the food was 
enough to oppose PDAC-associated desmoplasia, impede PanIN progression 
and reduce the amount of actively dividing cancer cells. 
 
This study highlights the great plasticity of tumour cells during tumour 
development. The authors pinpoint the critical role of the BCAA-Bcat2 axis at 
the onset of the disease and dissected the molecular mechanism explaining 
the upregulation of Bcat2 in the ductal cells that carry Kras mutation. Also, Li 
et al. suggest a possible therapeutic treatment based on a tailored dietary 
regimen. Proposing complementary diet together with pharmacological 
treatment against cancer is giving promising results in animal studies2, 11. A 
major challenge with dietary intervention will be to assess translatability to 
free-living human subjects. Furthermore, another interesting aspect identified 
in the treated animals by Li et al.4 was an important reduction of the 
desmoplastic stroma, which plays a fundamental role in both PDAC 




Figure 1: KRAS mutation boosts BCAA metabolism promoting PanIN 
development. Acquisition of KRAS mutation by pancreatic ductal cells leads 
to the inhibition of SYK, resulting in reduced activity of TRIM21 and increased 
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